Design of clinical trials in cystic fibrosis

Lancet. 2003 Jan 25;361(9354):349-50; aurhor reply 350. doi: 10.1016/S0140-6736(03)12352-5.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / therapeutic use*
  • Cystic Fibrosis / drug therapy*
  • Humans
  • Maximal Expiratory Flow Rate / drug effects
  • Patient Selection
  • Randomized Controlled Trials as Topic / methods*
  • Research Design

Substances

  • Anti-Bacterial Agents
  • Azithromycin